INTRODUCTION AND OBJECTIVES: B7-H3 is an immune checkpoint molecule widely expressed by prostate cancer, that exists in soluble form in the blood, and that impairs T cell function. We examined whether a cell-based immunotherapy for castrate-resistant prostate cancer (CRPC), sipuleucel-T, might modulate B7-H3 as part of its mechanism of action.
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METHODS: We conducted a clinical trial (NCT02036918) where men with lymph node predominant oligometastatic CRPC were randomized to undergo either (a) sipuleucel-T immunotherapy followed by salvage lymphadenectomy (n¼15) or (b) salvage lymphadenectomy followed by sipuleucel-T (n¼5). Serum samples were taken at baseline, prior to each sipuleucel-T leukapheresis session (x3), and two weeks after the last sipuleucel-T infusion. Serum samples were then tested in triplicate for soluble B7-H3 using a solid phase sandwich ELISA assay. The assay was calibrated against highly purified NS0-expressed recombinant human B7-H3. ELISA was performed in 90 well microplates that were read in a SpectraMax microplate reader at 450 nm with wavelength correction set to 540 nm. B7-H3 concentrations were calculated using a 4-parameter logistic model curve fit (Hill equation). Pre-and post-intervention serum B7-H3 levels were compared with a paired T test.
RESULTS: The mean minimum detectable dose of B7-H3 for the assay was 0.160 ng/mL. Vaccination with sipuleucel-T resulted in significant drop in serum B7-H3 levels from a mean pre-sipuleucel-T level of 29.6 ng/mL [SD ¼ 6.7] to a mean post-sipuleucel-T level of 24.0 ng/mL [SD ¼ 5.5] (P <0.001). In contradistinction, pre-surgery mean serum B7-H3 was 22.1 ng/mL (SD ¼ 5.5) and post-surgery mean serum B7-H3 was 29.2 ng/mL (SD ¼ 9.3), a difference of 7.1 ng/mL (P ¼ 0.002), indicating that surgery caused an increase in serum B7-H3 levels ( Figure) .
CONCLUSIONS: Sipuleucel-T immunotherapy is known to prolong survival in CRPC. Our results suggest that one potential mechanism of action of this vaccine (and possibly other prostate cancer vaccines) is to reduce the production of soluble B7-H3 by prostate cancer cells, which could lead to improved immune responsiveness of the host immune system. However, the postoperative inflammatory response may abrogate some of this benefit. predictor of biochemical recurrence (BCR). There is accumulating evidence to support a role of the autonomic nervous system in prostate cancer development and progression.We sought to investigate which autonomic nerve subtypes are involved in PNI in prostate cancer and how these relate to other clinical and pathological variables including BCR.
METHODS: Histological evaluation of biorepository radical prostatectomy tissue from 141 men with known PNI was undertaken to identify a cohort of men for inclusion, balanced for recurrence. Hotspot analysis of 3 medium-power fields of intraprostatic PNI, serially stained with S100 plus AE1/AE3, tyrosine hydroxylase (TH) and neuronal nitric oxide synthase (nNOS) were examined to identify PNI, sympathetic and parasympathetic nerves respectively. Histological results were correlated with clinical data from a prospectively collected database.
RESULTS: 98 men were included for analysis. Roughly equal numbers of participants had organ confined compared to locally advanced disease. 68% had Gleason 7 cancer. Overall 42% of the cohort experienced BCR, with follow-up time of 85 months (median) for men who did not recur. Mixed type bundles accounted for 71% of PNI nerves and 82% of non-PNI nerves. Total PNI nerve count and total pure sympathetic nerve counts both correlated with pT stage (p¼0.0056 and p¼0.025 respectively). Sympathetic non-PNI nerve count (HR 6.97, p¼0.03), and non-adrenergic, nonnitrergic PNI nerve count (HR 10.56, p<0.005) both independently predicted BCR.
CONCLUSIONS: Our work has revealed two independent predictors of BCR, and points towards a regulatory role of the autonomic nervous system in prostate cancer. A greater understanding of the mechanisms underpinning this relationship may translate into future therapeutic opportunities in prostate cancer. METHODS: Thirty-four men undergoing FLA between April 2013 and February 2015 participated in a longitudinal prospective outcomes study assessing complications, functional outcomes, and oncologic control. Our selection criteria and treatment protocol have been previously described (1). All candidates agreed to undergo post-FLA PSA testing every 6 months, mpMRI at 6 and 24 months, and reflex 4-core MRI-guided biopsy of the ablation zone at 6 and 24 months. A significant post-FLA PC was defined by > 1 core Gleason 6 or any Gleason > 6. RESULTS: Of the 34 men undergoing FLA, 2 never returned for follow-up. In 32 men, mpMRI was performed at two years unless a prior biopsy demonstrated PC. Oncologic outcomes were stratified according to positive (Table 1 ) and negative (Table 2) MRI findings. Of the 8 MRIpositive men, all had clinically significant PC on targeted biopsy. Of the 24 MRI-negative men, 9 (37%) had PC on biopsy, 5 (21%) were biopsy- Vol. 199, No. 4S, Supplement, Saturday, May 19, 2018 THE JOURNAL OF UROLOGY â e373
